Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

Sandhill Therapeutics

Main focus: Gene editing for next generation cellular therapies

Company stage: Pre-clinical

Diseases: Haematological- and solid tumours

Genome editing tool: CRISPR-Cas9 (Through Editas Medicine)

Funding stage: Private

Location: Dallas, Texas, USA


Partners: Editas Medicine

Sandhill’s proprietary technology, called BINATE™, leverages dual innate cell synergy, resulting in a highly activated, readily available, universal off-the-shelf treatment for both solid tumours and blood cancers. Through its collaboration with Editas Medicine, the company is developing next generation CRISPR-edited cellular therapies.


HashtagSandhill Therapeutics, Inc.

Company: Sandhill Therapeutics
Search CRISPR Medicine